Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1634 1671 1682 1683
This examiner grants 42% of resolved cases
Juliet Caroline Switzer works in Tech Center 1600 and Art Unit 1634. She has 516 resolved cases and an allowance rate of 42.4%. This rate suggests a rigorous examination process. However, the interview lift is exceptionally high at 54.0%, which is one of the most impactful metrics for this examiner.
The median days to allowance is 1359. This timeline indicates that prosecution in Art Unit 1634 can be lengthy. The 54.0% interview lift is a vital piece of information, as it suggests that an interview significantly improves the chances of success compared to the 42.4% baseline allowance rate. Practitioners should prioritize interviews when working with Switzer in Tech Center 1600. The 1359-day median is a critical factor for managing client expectations and planning for the duration of the prosecution cycle.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18692467 | METHODS AND MATERIALS FOR ASSESSING AND TREATING ORAL LICHEN PLANUS | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18210213 | METHODS OF DETECTING SIGNATURES OF DISEASE OR CONDITIONS IN BODILY FLUIDS | Final Rejection | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18288765 | METHOD FOR DIAGNOSING ACTIVE TUBERCULOSIS AND PROGRESSION TO ACTIVE TUBERCULOSIS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17783997 | ENHANCED DISEASE RESISTANCE OF MAIZE TO NORTHERN CORN LEAF BLIGHT BY A QTL ON CHROMOSOME 4 | Non-Final OA | KWS SAAT SE & Co. KGaA |
| 18251536 | RAPID IDENTIFICATION AND TYPING OF VIBRIO PARAHAEMOLYTICUS | Non-Final OA | Becton, Dickinson and Company |
| 18565854 | UNIQUE CANCER ASSOCIATED FIBROBLAST SUBSETS PREDICT RESPONSE TO IMMUNOTHERAPY | Non-Final OA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 18459733 | Methods To Analyze Methylomes In Tumor And Plasma Cell-Free DNA | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 17675589 | BIOMARKER COMPOSITION, DIAGNOSTIC KIT, AND METHOD FOR PROVIDING INFORMATION | Final Rejection | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18392826 | DETECTION OF ANALYTES USING TARGETED EPIGENETIC ASSAYS, PROXIMITY-INDUCED TAGMENTATION, STRAND INVASION, RESTRICTION, OR LIGATION | Non-Final OA | ILLUMINA, INC. |
| 18982106 | COMPOSITIONS AND METHODS OF USING HisGTG TRANSFER RNAS (tRNAs) | Non-Final OA | Thomas Jefferson University |
| 17958516 | METHODS OF DIAGNOSING CANCER AND PREDICTING RESPONSIVENESS TO THERAPY | Non-Final OA | Yeda Research and Development Co. Ltd. |
| 17720005 | Methods and Systems for Labelling Nucleic Acids | Non-Final OA | IMEC VZW |
| 17641650 | NOVEL GENETIC MARKERS FOR POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS) AND METHODS OF USE THEREOF FOR DIAGNOSIS AND TREATMENT OF THE SAME | Non-Final OA | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 18042434 | LAMP DETECTION OF SARS-COV-2 IN SALIVA FOR THE RAPID DIAGNOSIS OF COVID-19 | Final Rejection | CITY OF HOPE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy